Nanotech hep B vaccine could revolutionize therapy

Scientists at the University of Michigan are moving closer to human trials of a new nanoemulsion hepatitis B vaccine that could revolutionize therapy in the third world. The nanoemulsion approach avoids the work needed to keep syringes sterile, refrigeration and the repeated jabs required by current vaccines. The first human trial could launch in a year.

"Our results indicate needle-free nasal immunization, using a combination of nanoemulsion and hepatitis B antigen, could be a safe and effective hepatitis B vaccine, and also provide an alternative booster method for existing vaccines," said Dr. James Baker Jr., the study's senior author.

- check out the release
- read the UPI report

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.